Transfusion therapy


Published on

Published in: Health & Medicine, Business
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • King Louis XIV personal physician…..First recorded transfusion – lamb to human
  • Very mixed results with transfusions from 1818 - 1900
  • Transfusion therapy

    1. 1. TRANSFUSION THERAPY Dr.Sajid Nomani Deptt. Of Emergency medicine, Peerless hospital and B.K.Roy research centre Kolkkata.
    2. 2. ???………….A mcq A 22 yr old man sustain multiple penetrating wounds to upper rt.chest,his wounds are all above the nipple. He is intubated,closed tube thoracostomy is performed, and 1500ml of blood has drained from rt.chest,2 liters of crystalloid are infused. His BP is now 60/?,HR-160b/m The most appropriate next step in managing this pt. is a. Perform FAST b. Obtain a CT chest c. Perform an angiography d. Arrange transfusion & transfer to OT. e. Infuse colloids
    3. 3. 15thJune 1667 – Jean Baptiste Denys
    4. 4. Early 1800’s First successful human-human transfusion
    5. 5. 1902– Karl Landsteiner Won the 1930 Nobel Peace Prize Isolated the A, B, & O blood types. Type AB blood was identified two years later. Beginning of safe and effective transfusion medicine
    6. 6. RELATIONSHIP BETWEEN BLOOD TYPE & ANTIBODIES Blood type Antigen on RBC Can donate to Antibodies in serum Can receive from A A A & AB ANTI B A ,O B B B & AB ANTI A B ,O AB A &B AB NONE A ,B,O O NONE ALL ANTI A & ANTI B O
    7. 7. Well, it gets more complicated here, because there's another antigen to be considered – the Rh antigen. • Rh was 1st identified of a rhesus monkey → rhesus factor • A person with Rh factor on his RBC said to be Rh+ve • Will not make anti Rh antibodies • A person with out Rh factor on his RBC said to be Rh –ve • This will produce anti Rh antibodies • Rh incompatibility dangerous in pregnancy.
    8. 8. Term &Definitions BLOOD PRODUCT :Any therapeutic substance prepared from human blood WHOLE BLOOD :Unseparated blood BLOOD COMPONENT : A constituent of blood ,separated from Red cell concentrate PRBC FFP PLATELETS CRYOPRECIPITATE → Leucoreduced / Irradiated / washed
    9. 9. Why Separation of blood components ???? • The storage life of whole blood is less than that of individual components • Allows optimal survival for each component. • Allows transfusing specific blood components. • Several patients can be treated from one unit.
    10. 10. Decision making • Whom to transfuse? • What to transfuse? • How much to transfuse?
    11. 11. So…whom you would transfuse !!!! i. 23 yo asymptomatic, healthy woman with menorrhagia,Hb 8.0 g/dl,MCV- 72 fl ii. 61 yo,k/c/o Htn,with severe gram negative sepsis – BP-100/70,cold periphery,AMS & Hb 8.0 g/dl. iii. 54 yo woman post hemicolectomy Hb 8.0g/dl. iv. 73 yo man presenting with acute upper GI bleed; BP 80/60, Pulse 120 thready – Hb 8.0 g/dl,MCV- 90fl
    12. 12. Objectives of transfusion therapy • Maintain blood volume • Maintain O2 carrying capacity • Maintain coagulation • Red Cell Transfusion SHOULD not be solely used as a ‘plasma expander’ – but primarily as a method to increase oxygen carrying capacity.
    13. 13. So…what is threshold for transfusion ??? • Difficult to set a transfusion threshold that holds true for all patients. • Depends upon clinical status & co-morbidities. • Use "10/30― rule.
    14. 14. STATEMENT American society of Anaesthesiologists (ASA) state that: “Red blood cell transfusion is rarely indicated when the hemoglobin concentration is greater than 10 g/dl and is almost always indicated when it is less than 6 g/dl”
    15. 15. Transfusion guidelines have been published by the following societies: • American Society of Anesthesiology • British Committee for Standards in Hematology • Australian and New Zealand Society of Blood Transfusion • Eastern Association for Surgery of Trauma (EAST) & American College of Critical Care Medicine of the Society of Critical Care Medicine (SCCM) • European Society of Cardiology (ESC) • AABB (formerly the American Association of Blood Banks) • American College of Physicians
    16. 16. Some recommended threshold • Hgb <6 g/dL – Transfusion recommended . • Hgb 6 to 7 g/dL – Transfusion generally likely to be indicated • Hgb 7 to 8 g/dL – Transfusion should be considered in postoperative surg.pts. • • Hgb 8 to 10 g/dL – Transfusion generally not indicated, but should be considered for some populations (eg, those with symptomatic anemia, ongoing bleeding, acute coronary syndrome with ischemia) • Hgb >10 g/dL – Transfusion generally not indicated except in exceptional circumstances
    17. 17. • Transfusion Requirements in Critical Care (TRICC) Hebert PC, et al. N.Engl J Med. 1999;340(6):409-17 A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care has demonstrated that you can adopt a • transfusion threshold of 7 g/dL and maintain critically ill patients between 7 and 9 g/dL • Patients with acute MI and unstable angina may possibly benefit from Hb> 8 g/dL
    18. 18. Blood component….. Doses , Indications & Response
    19. 19. component indication Approx / U typical doses Doses effects PRBC 1 U=250ml Acute ongoing hemorrhage Sever symptomatic anaemia RBC-80% Hct-70% 2 units or 15ml/kg ↑Hb-2gm/dl ↑Hct-6% Platelets 1 U=250ml <10000/mm3 in asymptomatic pt. <20000/mm3 in major bleeding <50000/mm3 for invasive procedure <100,000/mm3 with neoro/cardiac surgery 1 unit or 5 mL/kg ↑50,000/mm3 but less in many cases (↑consumption/ Active thrombosis/ Destruction due to plt.antibodies.) 3–6 x 1011 FFP 1 U=250 ml 1 u of each coagl.factor & Fibrinogen- 2mg/ml Coagulation Factor deficiency, fibrinogen replacement, DIC, liver disease, exchange transfusion massive transfusion, warfarin overcoagulation effect Cryoprecipi -tate 1U=50ml Four units or 15 mL/kg Raises most coagulation factors levels approx. 20% Fibrinogen / factor VIII / vWF / factor XIII /fibronectin. 10 units or 1 unit/5 kg Raises fibrinogen 75 milligrams/dL Bleeding with a fibrinogen level of <100 milligrams/dL Fibrinogen deficiency vonWillebrands Disease Factor VIII or XIII deficiency
    20. 20. Special processing of RBC leukocyte-reduced PRBCs •↓nonhemolytic febrile reactions. •↓ risk of virus transmission. •to prevent sensitization in pt. for bone marrow transplantation Irradiated PRBCs should be considered in transplant patients, neonates, and immunocompromised patients washed PRBCs •↓risk of anaphylaxis in IgA deficient pt. •↓risk of reaction in pt.with recurrent / severe allergic reaction to blood products.
    21. 21. Massive Transfusion • 10 units of PRBCs within a 24-hour period. • Replacement of a blood volume equivalent within 24hr • >10 unit within 24 hr • Transfusion > 4 units in 1 hr • Replacement of 50% of blood volume in 5 hrs • A rate of loss >150ml/hr
    22. 22. Importance of Massive Transfusion • 39% of trauma related deaths – uncontrollable bleeding (Leading cause of preventable death) • 2% of trauma patients – need massive transfusion • Bleeding 2 main causes • Vascular injury (surgical) • Coagulopathy (non-surgical)
    23. 23. Haemorrhage Hypotension Resuscitation Haemodilution Coagulopathy HypothermiaLethal triad
    24. 24. So.....What is Haemostatic /damage control Resuscitation? • A ground breaking concept! • Prevents post traumatic coagulopathy • Aims to reduce use of blood products in the intensive care phase. Expert’s openion RBC:FFP:PLT 1:1:1 Traditionally PLT: <50,000/mm3 FFP : INR >1.5 Crypts : fibrinogen <100ml/dl
    25. 25. Evidence of Haemostatic Resuscitation • Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol Debra L Malone, John R Hess, Abe Fingerhut ;The Journal of trauma. 01/07/2006; 60(6 Suppl):S91-6. Suggested – RBC:FFP - 1:1 • Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma Lloyd Ketchum, John R Hess, Seppo Hiippala; The Journal of trauma. 01/07/2006; 60(6 Suppl):S51-8. Early use of FFP,PLT - ↓ incidence of coagulopathy
    26. 26. Transfusion’s Complications • Up to 20% may lead to some type of adverse reaction. • Mostly within 24 h. • Most are minor reactions./ don’t miss the life threatening • Acute vs Delayed reaction. • Infectious & non infectious. • Difficult to recognized in Critically ill patient
    27. 27. Acute Transfusion Reactions • Hemolytic Reactions (AHTR) • Febrile Reactions (FNHTR) • Allergic Reactions • TRALI • Coagulopathy with Massive transfusions
    28. 28. AHTR 1 to 4 per 1 million units transfused. Most commonly by ABO incompatibility. Transfused cells are destroyed ↓ ↓ ↓ Activation of the coagulation system with DIC & release of Anaphylotoxins & other vasoactive amines ↓ ↓ ↓ • High fever/chills • Hypotension • Back/abdominal pain • Oliguria / Hemoglobinuria • Dyspnea • Pallor • requires a high degree of suspicion in critically ill
    29. 29. What to do? If an AHTR occurs • STOP TRANSFUSION • A /B /C’s • Maintain IV • Give diuretic • Blood & urine transfusion reaction workup • Send remaining blood back to Blood Bank Renal st-BUN/ Creat Hemolysis-Bill/LDH/haptoglobin
    30. 30. Febrile transfusion reaction Commenst among all 1 per 300 units of PRBC infused & 20% of plt.infusion. Result from a combination of recipient antibody against donor leukocytes and the release of cytokines that are produced during storage. Pretreatment with acetaminophen can mask this reaction. • Rise in patient temperature >1 C (associated with transfusion without other fever precipitating factors) • fever / chills, • Headache / myalgias, • Tachycardia /dyspnea /chest pain. • difficult to differentiate from more serious hemolytic transfusion reaction or sepsis.
    31. 31. What to do?If an FNHTR occurs • STOP TRANSFUSION • Use of Antipyretics • Suspect and manage as AHTR • Initially difficult to distinguish between the two. • Use of Corticosteroids for severe reactions • Use of Narcotics for shaking chills • Future considerations • May prevent reaction with leukocyte filter. • Use single donor platelets • Use fresh platelets. • Washed RBC’s or platelets
    32. 32. Transfusion Related Acute Lung injury (TRALI) • Clinical syndrome similar to ARDS • Transfusion related noncardiogenic pulmonary edema • Usually after FFP & Platelets transfusion • Rare but , most common cause of transfusion related death • Caused by WBC antibodies present in donor blood that result in pulmonary leukostasis • Occurs 1-6 hours after receiving plasma-containing blood products • High mortality
    33. 33. TRALI Criteria • Acute onset dyspnea during or within 6 hours of transfusion • Clinical evidence of hypoxemia • Bilateral infiltrates on frontal chest radiograph • No evidence of left atrial hypertension (i.e. circulatory overload) • Absence of other attributable causes Treatment is supportive
    34. 34. DELAYED REACTION • Alloimmunization • Transfusion Associated Graft Verses Host disease (GVHD) • Iron Overload • Transfusion Transmitted Infection
    35. 35. Alloimmunization • Can occur with erythrocytes or platelets • Erythrocytes • Antigen disparity of minor antigens (Kell, Duffy, Kidd) • Minor antigens D, K, E seen in Sickle patients • Platelets • Usually due to HLA antigens • May reduce alloimmunization by leukoreduction (since WBC’s present the HLA antigens)
    36. 36. Transfusion Associated GVHD • Mainly seen in infants • Etiology—Results from engraftment of donor lymphocytes of an immunocompetent donor into an immunocompromised host • Symptoms—Diarrhea, skin rash, pancytopenia • Usually fatal—no treatment • Prevention—Irradiation of donor cells
    37. 37. Etiology Estimated Frequency: One Infection per Number of Units Transfused HIV-1 1 per 2–3 million HIV-2 Unknown, but extremely low Human T-cell lymphotrophic virus type I and II 1 per 640,000 Hepatitis B 1 per 100,000–200,000 Hepatitis C 1 per 1–2 million Parvovirus B19 1 per 10,000 Bacterial sepsis 1 per 6 million platelet concentrates 1 per 500,000 packed red blood cells
    38. 38. • THANKS YOU